Robert Werling - MD

 
Robert Werling - MD

Make an Appointment

To request an appointment online,
log into MyChart.
My Areas of Practice

When I joined the department in 2008, I brought five years of clinical experience in dermopathology to the Park Nicollet Dermatology department. I enjoy teaching pathology to dermatologists and residents, having three times received the University of Minnesota Dermatology Department’s Teacher of the Year Award (2006, 2008, and 2011). While I have lectured and published on a variety of topics within the broad field of dermatology, I am particularly interested in melanocyte pathology, inflammatory dermatoses, and immunohistochemistry. 

General Information

Gender: Male

Services

Practices at

St Louis Park
3800, 3850 and 3900 Park Nicollet Blvd.
St. Louis Park, MN 55416

Education & Certifications

Dermpath Fellowship: Ohio State University - Columbus, OH
Dermatopathology
Columbus
2003

Certification: American Board of Pathology, Anatomic and Clinical
2000

Diagnostic Immunohistochemistry Fellowship: PhenoPath Lab - Seattle, WA
2002

Anatomic/Clinical Pathology Residency: Univ. of WA Medical Center - Seattle
2000

Pre-med: University of Washington - Seattle

MD: University of Washington - Seattle
1996

BA: Yale University - New Haven, CT
1986

Certification: American Board of Dermatology
2003

Research & Publications

1.                  T-cell clonality determination using polymerase chain reaction amplification of the T-cell receptor gamma-chain gene and capillary electrophoresis of fluorescently labeled products.  J Sprouse, RW Werling, D Hanke, C Lakey, L McDonnel, BL Wood, DE Sabath.  American Journal of Clinical Pathology (2000) 113:838-850.   Recipient of University of Washington Department of Laboratory Medicine’s Strandjord Clayson Award for “meritorious research.”

 

2.                  Distribution of Tissue Factor Pathway Inhibitor (TFPI) in normal and malignant human tissues.  RW Werling, LR Zacharski, W Kisiel, SP Bajaj, VA Memoli, SM Rousseau.  Thrombosis and Hemostasis, 69 (4) 366-9 (1993).

 

3.                  CDX-2 is a highly sensitive and specific marker of adenocarcinomas of the colorectum and gastrointestinal tract:  an immunohistochemical survey of 426 primary and metastatic carcinomas.  RW Werling, H Yaziji, C Bacchi, AM Gown. American Journal of Surgical Pathology, 2003 Mar;27(3):303-10.

 

4.                  Immunohistochemical distinction of invasive from non-invasive breast lesions:  a comparative study of p63 vs. calponin and smooth muscle myosin heavy chain.  RW Werling, H Hwang, H Yaziji, and AM Gown. American Journal of Surgical Pathology, 2003 Jan;27(1):82-90.

 

5.                  HER-2 testing in breast cancer using parallel tissue-based methods.  H Yaziji, LC Goldstein, TS Barry, RW Werling, H Hwang, GK Ellis, JR Gralow, RB Livingston, AM Gown. Journal of the American Medical Association, 2004; 291:1972-1977.

 

6.                  Assessment of T cell clonality via TCR gamma rearrangements in cutaneous T cell-dominant infiltrates using PCR and Single-Stranded DNA Conformational Polymorphism Assay. M Chen, A Deng, AN Crowson, M Srinivasan, K Yearsley, S Jewell, C Morrison, S Long, RW Werling, C Magro. Applied Immunohistochemistry and Molecular Morphol, 2004 Dec;12(4):373-9.

 

7.                  Primary cutaneous CD30+ large cell B-cell lymphoma: a series of 10 cases. C Magro, JW Nash , RW Werling, P Porcu, AN Crowson. Appl Immunohistochem Mol Morphol, 2006 Mar;14(1):7-11.

 

8.                  Hypertrophic lupus erythematosus, clinical pathologic challenge. P Suwattee, PM Cham, RW Werling, VN

Professional Associations & Awards

  • Minnesota Dermatological Society
  • American Society of Clinical Pathology
  • American Academy of Dermatology
  • Teacher of the Year, University of Minnesota Dermatology Department, 2006, 2008, 2011

Personal